Sales in the extended release drugs market are expected to rise at a CAGR of 11% over the forecast period 2022 to 2032. Extended-release drugs market is currently valued at USD 48 Billion.
Due to changes in prescription patterns and rising acceptance of diverse dosage forms, demand for extended-release drugs is anticipated to bolster in the forthcoming years.
| Report Attribute | Details |
|---|---|
| Extended Release Drugs Market Size (2022) | USD 48 Billion |
| Extended Release Drugs Market Projected Growth Rate (2022 to 2032) | 11% CAGR |
Conventional drugs release the active ingredient as soon as they are administered. Drug delivery systems are planned technologies that deliver the active ingredient in a controlled environment, controlling the time, rate, and area of drug release in the body. These systems have been proven to be safe and efficient.
Extended-release drugs are a dosage formulation that reduces the dosage by half. There are specific regulations released by the FDA that extended release drugs need to comply with.
Growing adoption of various drug delivery systems by doctors and patients, safety and effectiveness of extended drug release, and a reduction in medical care expenditure due to extended-release drugs will create a conducive environment for growth in the market.
Compared to conventional oral drugs, extended-release drugs are well-planned administration of medication. Extended-release drugs control the time, area, and rate of the dosage, thereby increasing safety and efficacy. With the controlled release of the active ingredient, extended-release drugs also help to reduce the frequency of dosage, resulting in easier and better acceptance by patients as well as increased bioavailability.
Growing demand for pediatric and geriatric extended drug release formulations, widespread acceptance of extended drug release systems, and notable changes in the prescription pattern of doctors will drive the market.
Advancing research & development, ongoing clinical trials in the pharmaceutical sector, and a greater focus on the development of new and innovative therapeutics will further bolster the market for extended drug release.
The cost of extended drug release is a major roadblock for manufacturers. A single unit of extended-release drugs costs double or triple the conventional oral dosage. The price of Namenda's extended-release drug is around USD 494 for 7mg. This is expected to limit sales in the market.
Conventional drugs have an almost immediate impact whereas extended-release drugs take a comparatively long time to make an impact as they have a slower course of action.
Side effects such as dose dumping could seriously affect health, which might hamper the growth of the market.
Dose dumping is the quick release of extended-release drugs in the circulatory system and can lead to toxicity. Refusal of extended-release drugs due to bad taste or swallowing difficulties is another factor that may impede demand in the forthcoming years.
Owing to the introduction of new and innovative therapeutics and their widespread acceptance, North America holds a significant share of the global extended-release drugs market.
The presence of leading pharmaceutical and biopharmaceutical companies, along with increasing investments in research and development in the pharmaceutical sector will propel the growth in the North American extended-release drug market.
The growing burden of chronic diseases and the adoption of extended-release drugs in the treatment of hypertension will further underpin the demand for extended-release drugs.
Increasing adoption of extended-release drugs across countries such as Germany, the United Kingdom, Italy, and France is expected to boost the Europe extended-release market over the assessment period.
The rising incidence of chronic diseases such as COPD, diabetes, and cancer has led to quicker adoption of extended-release drugs. This is expected to create opportunities for extended-release drug manufacturers operating in Europe.
As per FMI, Asia Pacific is predicted to display the highest CAGR during the forecast period. The region has shown great potential in the extended-release drugs market due to the rapid growth of the pharmaceutical industry.
The ongoing expansion of the pharmaceutical and biopharmaceutical sectors across countries including China and India is anticipated to steer sales in the Asia Pacific extended-release drugs market.
Some of the key players in the global extended-release drugs market are Pfizer, Mallinckrodt, Actavis, Janssen Pharmaceuticals, Endo Pharmaceuticals, Purdue Pharma, Lavipharm Labs, Mylan Technologies, Noven, Aveva, Watson, Impax, Ranbaxy.
The global extended-release drug market is highly competitive with leading companies focusing on developing novel therapeutics. Mergers and acquisitions are the go-to strategies adopted by key players to expand their product portfolios.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR 11% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2015 to 2021 |
| Forecast Period | 2022 to 2032 |
| Quantitative Units | Revenue in USD Million, and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Drug Release, Distribution Channel, Region |
| Countries Covered | North America (USA, Canada); Latin America (Mexico, Brazil); Western Europe (Germany, Italy, France, United Kingdom, Spain, Nordic countries, Belgium, Netherlands, Luxembourg); Eastern Europe (Poland, Russia); Asia-Pacific Excluding Japan (China, India, ASEAN, Australia & New Zealand); Japan; The Middle East and Africa (GCC, S. Africa, N. Africa) |
| Key Companies Profiled | Pfizer; Mallinckrodt; Actavis; Janssen Pharmaceuticals; Endo Pharmaceuticals; Purdue Pharma; Lavipharm Labs; Mylan Technologies; Noven; Aveva; Watson; Impax; Ranbaxy |
| Customization | Available Upon Request |
Table 1: Global Market Value (US$ Million) Forecast by Region, 2017 to 2032
Table 2: Global Market Volume (Tons) Forecast by Region, 2017 to 2032
Table 3: Global Market Value (US$ Million) Forecast by Drug Release, 2017 to 2032
Table 4: Global Market Volume (Tons) Forecast by Drug Release, 2017 to 2032
Table 5: Global Market Value (US$ Million) Forecast by Distributional Channel, 2017 to 2032
Table 6: Global Market Volume (Tons) Forecast by Distributional Channel, 2017 to 2032
Table 7: North America Market Value (US$ Million) Forecast by Country, 2017 to 2032
Table 8: North America Market Volume (Tons) Forecast by Country, 2017 to 2032
Table 9: North America Market Value (US$ Million) Forecast by Drug Release, 2017 to 2032
Table 10: North America Market Volume (Tons) Forecast by Drug Release, 2017 to 2032
Table 11: North America Market Value (US$ Million) Forecast by Distributional Channel, 2017 to 2032
Table 12: North America Market Volume (Tons) Forecast by Distributional Channel, 2017 to 2032
Table 13: Latin America Market Value (US$ Million) Forecast by Country, 2017 to 2032
Table 14: Latin America Market Volume (Tons) Forecast by Country, 2017 to 2032
Table 15: Latin America Market Value (US$ Million) Forecast by Drug Release, 2017 to 2032
Table 16: Latin America Market Volume (Tons) Forecast by Drug Release, 2017 to 2032
Table 17: Latin America Market Value (US$ Million) Forecast by Distributional Channel, 2017 to 2032
Table 18: Latin America Market Volume (Tons) Forecast by Distributional Channel, 2017 to 2032
Table 19: Europe Market Value (US$ Million) Forecast by Country, 2017 to 2032
Table 20: Europe Market Volume (Tons) Forecast by Country, 2017 to 2032
Table 21: Europe Market Value (US$ Million) Forecast by Drug Release, 2017 to 2032
Table 22: Europe Market Volume (Tons) Forecast by Drug Release, 2017 to 2032
Table 23: Europe Market Value (US$ Million) Forecast by Distributional Channel, 2017 to 2032
Table 24: Europe Market Volume (Tons) Forecast by Distributional Channel, 2017 to 2032
Table 25: East Asia Market Value (US$ Million) Forecast by Country, 2017 to 2032
Table 26: East Asia Market Volume (Tons) Forecast by Country, 2017 to 2032
Table 27: East Asia Market Value (US$ Million) Forecast by Drug Release, 2017 to 2032
Table 28: East Asia Market Volume (Tons) Forecast by Drug Release, 2017 to 2032
Table 29: East Asia Market Value (US$ Million) Forecast by Distributional Channel, 2017 to 2032
Table 30: East Asia Market Volume (Tons) Forecast by Distributional Channel, 2017 to 2032
Table 31: South Asia & Pacific Market Value (US$ Million) Forecast by Country, 2017 to 2032
Table 32: South Asia & Pacific Market Volume (Tons) Forecast by Country, 2017 to 2032
Table 33: South Asia & Pacific Market Value (US$ Million) Forecast by Drug Release, 2017 to 2032
Table 34: South Asia & Pacific Market Volume (Tons) Forecast by Drug Release, 2017 to 2032
Table 35: South Asia & Pacific Market Value (US$ Million) Forecast by Distributional Channel, 2017 to 2032
Table 36: South Asia & Pacific Market Volume (Tons) Forecast by Distributional Channel, 2017 to 2032
Table 37: MEA Market Value (US$ Million) Forecast by Country, 2017 to 2032
Table 38: MEA Market Volume (Tons) Forecast by Country, 2017 to 2032
Table 39: MEA Market Value (US$ Million) Forecast by Drug Release, 2017 to 2032
Table 40: MEA Market Volume (Tons) Forecast by Drug Release, 2017 to 2032
Table 41: MEA Market Value (US$ Million) Forecast by Distributional Channel, 2017 to 2032
Table 42: MEA Market Volume (Tons) Forecast by Distributional Channel, 2017 to 2032
Figure 1: Global Market Value (US$ Million) by Drug Release, 2022 to 2032
Figure 2: Global Market Value (US$ Million) by Distributional Channel, 2022 to 2032
Figure 3: Global Market Value (US$ Million) by Region, 2022 to 2032
Figure 4: Global Market Value (US$ Million) Analysis by Region, 2017 to 2032
Figure 5: Global Market Volume (Tons) Analysis by Region, 2017 to 2032
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2022 to 2032
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2022 to 2032
Figure 8: Global Market Value (US$ Million) Analysis by Drug Release, 2017 to 2032
Figure 9: Global Market Volume (Tons) Analysis by Drug Release, 2017 to 2032
Figure 10: Global Market Value Share (%) and BPS Analysis by Drug Release, 2022 to 2032
Figure 11: Global Market Y-o-Y Growth (%) Projections by Drug Release, 2022 to 2032
Figure 12: Global Market Value (US$ Million) Analysis by Distributional Channel, 2017 to 2032
Figure 13: Global Market Volume (Tons) Analysis by Distributional Channel, 2017 to 2032
Figure 14: Global Market Value Share (%) and BPS Analysis by Distributional Channel, 2022 to 2032
Figure 15: Global Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022 to 2032
Figure 16: Global Market Attractiveness by Drug Release, 2022 to 2032
Figure 17: Global Market Attractiveness by Distributional Channel, 2022 to 2032
Figure 18: Global Market Attractiveness by Region, 2022 to 2032
Figure 19: North America Market Value (US$ Million) by Drug Release, 2022 to 2032
Figure 20: North America Market Value (US$ Million) by Distributional Channel, 2022 to 2032
Figure 21: North America Market Value (US$ Million) by Country, 2022 to 2032
Figure 22: North America Market Value (US$ Million) Analysis by Country, 2017 to 2032
Figure 23: North America Market Volume (Tons) Analysis by Country, 2017 to 2032
Figure 24: North America Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 25: North America Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 26: North America Market Value (US$ Million) Analysis by Drug Release, 2017 to 2032
Figure 27: North America Market Volume (Tons) Analysis by Drug Release, 2017 to 2032
Figure 28: North America Market Value Share (%) and BPS Analysis by Drug Release, 2022 to 2032
Figure 29: North America Market Y-o-Y Growth (%) Projections by Drug Release, 2022 to 2032
Figure 30: North America Market Value (US$ Million) Analysis by Distributional Channel, 2017 to 2032
Figure 31: North America Market Volume (Tons) Analysis by Distributional Channel, 2017 to 2032
Figure 32: North America Market Value Share (%) and BPS Analysis by Distributional Channel, 2022 to 2032
Figure 33: North America Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022 to 2032
Figure 34: North America Market Attractiveness by Drug Release, 2022 to 2032
Figure 35: North America Market Attractiveness by Distributional Channel, 2022 to 2032
Figure 36: North America Market Attractiveness by Country, 2022 to 2032
Figure 37: Latin America Market Value (US$ Million) by Drug Release, 2022 to 2032
Figure 38: Latin America Market Value (US$ Million) by Distributional Channel, 2022 to 2032
Figure 39: Latin America Market Value (US$ Million) by Country, 2022 to 2032
Figure 40: Latin America Market Value (US$ Million) Analysis by Country, 2017 to 2032
Figure 41: Latin America Market Volume (Tons) Analysis by Country, 2017 to 2032
Figure 42: Latin America Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 43: Latin America Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 44: Latin America Market Value (US$ Million) Analysis by Drug Release, 2017 to 2032
Figure 45: Latin America Market Volume (Tons) Analysis by Drug Release, 2017 to 2032
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Drug Release, 2022 to 2032
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Drug Release, 2022 to 2032
Figure 48: Latin America Market Value (US$ Million) Analysis by Distributional Channel, 2017 to 2032
Figure 49: Latin America Market Volume (Tons) Analysis by Distributional Channel, 2017 to 2032
Figure 50: Latin America Market Value Share (%) and BPS Analysis by Distributional Channel, 2022 to 2032
Figure 51: Latin America Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022 to 2032
Figure 52: Latin America Market Attractiveness by Drug Release, 2022 to 2032
Figure 53: Latin America Market Attractiveness by Distributional Channel, 2022 to 2032
Figure 54: Latin America Market Attractiveness by Country, 2022 to 2032
Figure 55: Europe Market Value (US$ Million) by Drug Release, 2022 to 2032
Figure 56: Europe Market Value (US$ Million) by Distributional Channel, 2022 to 2032
Figure 57: Europe Market Value (US$ Million) by Country, 2022 to 2032
Figure 58: Europe Market Value (US$ Million) Analysis by Country, 2017 to 2032
Figure 59: Europe Market Volume (Tons) Analysis by Country, 2017 to 2032
Figure 60: Europe Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 61: Europe Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 62: Europe Market Value (US$ Million) Analysis by Drug Release, 2017 to 2032
Figure 63: Europe Market Volume (Tons) Analysis by Drug Release, 2017 to 2032
Figure 64: Europe Market Value Share (%) and BPS Analysis by Drug Release, 2022 to 2032
Figure 65: Europe Market Y-o-Y Growth (%) Projections by Drug Release, 2022 to 2032
Figure 66: Europe Market Value (US$ Million) Analysis by Distributional Channel, 2017 to 2032
Figure 67: Europe Market Volume (Tons) Analysis by Distributional Channel, 2017 to 2032
Figure 68: Europe Market Value Share (%) and BPS Analysis by Distributional Channel, 2022 to 2032
Figure 69: Europe Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022 to 2032
Figure 70: Europe Market Attractiveness by Drug Release, 2022 to 2032
Figure 71: Europe Market Attractiveness by Distributional Channel, 2022 to 2032
Figure 72: Europe Market Attractiveness by Country, 2022 to 2032
Figure 73: East Asia Market Value (US$ Million) by Drug Release, 2022 to 2032
Figure 74: East Asia Market Value (US$ Million) by Distributional Channel, 2022 to 2032
Figure 75: East Asia Market Value (US$ Million) by Country, 2022 to 2032
Figure 76: East Asia Market Value (US$ Million) Analysis by Country, 2017 to 2032
Figure 77: East Asia Market Volume (Tons) Analysis by Country, 2017 to 2032
Figure 78: East Asia Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 79: East Asia Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 80: East Asia Market Value (US$ Million) Analysis by Drug Release, 2017 to 2032
Figure 81: East Asia Market Volume (Tons) Analysis by Drug Release, 2017 to 2032
Figure 82: East Asia Market Value Share (%) and BPS Analysis by Drug Release, 2022 to 2032
Figure 83: East Asia Market Y-o-Y Growth (%) Projections by Drug Release, 2022 to 2032
Figure 84: East Asia Market Value (US$ Million) Analysis by Distributional Channel, 2017 to 2032
Figure 85: East Asia Market Volume (Tons) Analysis by Distributional Channel, 2017 to 2032
Figure 86: East Asia Market Value Share (%) and BPS Analysis by Distributional Channel, 2022 to 2032
Figure 87: East Asia Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022 to 2032
Figure 88: East Asia Market Attractiveness by Drug Release, 2022 to 2032
Figure 89: East Asia Market Attractiveness by Distributional Channel, 2022 to 2032
Figure 90: East Asia Market Attractiveness by Country, 2022 to 2032
Figure 91: South Asia & Pacific Market Value (US$ Million) by Drug Release, 2022 to 2032
Figure 92: South Asia & Pacific Market Value (US$ Million) by Distributional Channel, 2022 to 2032
Figure 93: South Asia & Pacific Market Value (US$ Million) by Country, 2022 to 2032
Figure 94: South Asia & Pacific Market Value (US$ Million) Analysis by Country, 2017 to 2032
Figure 95: South Asia & Pacific Market Volume (Tons) Analysis by Country, 2017 to 2032
Figure 96: South Asia & Pacific Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 97: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 98: South Asia & Pacific Market Value (US$ Million) Analysis by Drug Release, 2017 to 2032
Figure 99: South Asia & Pacific Market Volume (Tons) Analysis by Drug Release, 2017 to 2032
Figure 100: South Asia & Pacific Market Value Share (%) and BPS Analysis by Drug Release, 2022 to 2032
Figure 101: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Drug Release, 2022 to 2032
Figure 102: South Asia & Pacific Market Value (US$ Million) Analysis by Distributional Channel, 2017 to 2032
Figure 103: South Asia & Pacific Market Volume (Tons) Analysis by Distributional Channel, 2017 to 2032
Figure 104: South Asia & Pacific Market Value Share (%) and BPS Analysis by Distributional Channel, 2022 to 2032
Figure 105: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022 to 2032
Figure 106: South Asia & Pacific Market Attractiveness by Drug Release, 2022 to 2032
Figure 107: South Asia & Pacific Market Attractiveness by Distributional Channel, 2022 to 2032
Figure 108: South Asia & Pacific Market Attractiveness by Country, 2022 to 2032
Figure 109: MEA Market Value (US$ Million) by Drug Release, 2022 to 2032
Figure 110: MEA Market Value (US$ Million) by Distributional Channel, 2022 to 2032
Figure 111: MEA Market Value (US$ Million) by Country, 2022 to 2032
Figure 112: MEA Market Value (US$ Million) Analysis by Country, 2017 to 2032
Figure 113: MEA Market Volume (Tons) Analysis by Country, 2017 to 2032
Figure 114: MEA Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 115: MEA Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 116: MEA Market Value (US$ Million) Analysis by Drug Release, 2017 to 2032
Figure 117: MEA Market Volume (Tons) Analysis by Drug Release, 2017 to 2032
Figure 118: MEA Market Value Share (%) and BPS Analysis by Drug Release, 2022 to 2032
Figure 119: MEA Market Y-o-Y Growth (%) Projections by Drug Release, 2022 to 2032
Figure 120: MEA Market Value (US$ Million) Analysis by Distributional Channel, 2017 to 2032
Figure 121: MEA Market Volume (Tons) Analysis by Distributional Channel, 2017 to 2032
Figure 122: MEA Market Value Share (%) and BPS Analysis by Distributional Channel, 2022 to 2032
Figure 123: MEA Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022 to 2032
Figure 124: MEA Market Attractiveness by Drug Release, 2022 to 2032
Figure 125: MEA Market Attractiveness by Distributional Channel, 2022 to 2032
Figure 126: MEA Market Attractiveness by Country, 2022 to 2032
Due to the rapid growth of the pharmaceutical industry, especially in India and China, Asia Pacific is expected to emerge as an attractive market for extended-release drugs.
Leading players present in the global extended-release drug market include Pfizer, Mallinckrodt, Actavis, Janssen Pharmaceuticals, Endo Pharmaceuticals, Purdue Pharma, Lavipharm Labs, Mylan Technologies, Noven, Aveva, Watson, Impax, and Ranbaxy.
Rising demand for pediatric and geriatric extended-drug-release formulations and ongoing clinical trials in the pharmaceutical sector are some trends that are expected to drive sales of extended-release drugs.
Explore Similar Insights
Extended Release Drugs Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
